Matthew A. Gibbs
Matthew Gibbs is a General Partner of Oxford Bioscience Partners which is an early stage life science venture capital firm. The Partners of Oxford invested $1.1 billion in 149 companies, generating 31 IPOs and 45 M&A transactions.Mr. Gibbs has 20 years of investing experience in venture backed healthcare and technology companies. Mr. Gibbs joined Oxford Bioscience Partners in 1997 and became a General Partner in 2005. Current and past investments include Stratagene (life science instruments and reagents) acquired by Agilent (NYSE: A) for $250M, BioSource (life science reagents) acquired by Invitrogen (NASDAQ: IVGN) for $130M, Zone Labs (security software) acquired by CheckPoint Software Technologies (NASDAQ: CHKP) for $290M, eSionic (energy storage company for lithium ion batteries) and Cambrios (electronic materials for touch panel displays). Prior to joining Oxford, Mr. Gibbs worked for the Venture Fund of Washington, a venture capital firm. In 1994, Mr. Gibbs worked for MedVest, Inc a venture capital syndicated fund with Oak Investment Partners and Johnson and Johnson Development Corp. Mr. Gibbs received his B.A. from the University of Colorado and completed Executive Programs at Harvard Business School. He lives in Boston with his wife and twin daughters.
Back to OBP Team